文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌超分割加速再程放疗的疗效与毒性分析

Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.
PubMed 文献 · Radiother Oncol · 2017-01-03

本研究回顾性分析了102例复发直肠腺癌患者接受骨盆超分割加速再程放疗(1.5Gy每日两次,总剂量30-45Gy,中位39Gy)的结果。中位随访40个月,3年无局部进展生存率为40%,总生存率为39%;接受手术者FFLP和OS显著改善,但3-4级晚期毒性发生率更高。

要点

  • 超分割加速再程放疗耐受性良好,3年FFLP为40%,OS为39%。
  • 再程放疗联合手术者3年FFLP 49% vs 30%(P=0.013),OS 62% vs 20%(P<0.0001)。
  • 手术患者3-4级晚期毒性发生率显著更高(54% vs 16%,P=0.001)。

核心结论

  • 超分割加速再程放疗对复发直肠癌耐受性良好,FFLP率在经重度治疗的患者中令人鼓舞。
  • 再程放疗联合手术者的FFLP和OS尤其突出,但3-4级晚期毒性发生率更高。

研究设计与样本

  • 回顾性单中心研究,纳入102例复发直肠腺癌患者。
  • 再程放疗采用1.5Gy每日两次,总剂量30-45Gy(中位39Gy),最常见总剂量39Gy(n=90,88%)。
  • 既往骨盆放疗中位剂量50.4Gy(范围25-63Gy)。

主要发现

  • 中位随访40个月(存活患者范围3-150个月)。
  • 3年无局部进展生存率为40%,3年总生存率为39%。
  • 手术组与非手术组3年FFLP为49% vs 30%(P=0.013),3年OS为62% vs 20%(P<0.0001)。
  • 3年3-4级晚期毒性发生率为34%,手术组显著高于非手术组(54% vs 16%,P=0.001)。

临床怎么用

  • 对于复发直肠癌,超分割加速再程放疗是一种可考虑的再程放疗方案。
  • 再程放疗联合手术可能改善局部控制和生存,但需权衡晚期毒性风险增加。

局限性

  • 回顾性单中心研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To evaluate outcomes and toxicity in patients treated with hyperfractionated pelvic reirradiation for recurrent rectal cancer. MATERIALS AND METHODS: 102 patients with recurrent rectal adenocarcinoma were treated with pelvic reirradiation with a hyperfractionated accelerated approach, consisting of 1.5Gy twice daily fractions to a total dose of 30-45Gy (median 39Gy), with the most common total dose 39Gy (n=90, 88%). The median dose of prior pelvic radiation therapy (RT) was 50.4Gy (range: 25-63Gy). RESULTS: The median follow-up was 40months for living patients (range, 3-150months). The 3-year freedom from local progression (FFLP) rate was 40% and the 3-year overall survival (OS) rate was 39%. Treatment with surgery was significantly associated with improved FFLP and OS, with 3-year FFLP rate of 49% vs. 30% (P=0.013), and 3-year OS rate of 62% vs. 20% (P<0.0001), compared to those without surgery. The actuarial 3-year rate of grade 3-4 late toxicity was 34%; patients who underwent surgery had a significantly higher rate of grade 3-4 late toxicity compared to those without surgery (54% vs. 16%, P=0.001). CONCLUSIONS: This large, retrospective, single-institution study shows that hyperfractionated accelerated reirradiation was well tolerated. The rate of FFLP was promising, given that the study comprised heavily pre-treated patients with recurrences. Rates of FFLP and OS were particularly impressive in patients who underwent both reirradiation and surgery.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tao R, Tsai CJ, Jensen G, et al. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017. PMID: 28057329. doi:10.1016/j.radonc.2016.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。